- Home
- WERN vs NRIX Comparison
WERN vs NRIX Comparison
Compare WERN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WERN | NRIX |
|---|---|---|
| Founded | 1956 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WERN | NRIX |
|---|---|---|
| Price | $35.05 | $15.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $31.21 | $29.46 |
| AVG Volume (30 Days) | ★ 1.4M | 786.8K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.64% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,974,396,000.00 | $76,987,000.00 |
| Revenue This Year | $21.37 | N/A |
| Revenue Next Year | $6.93 | $29.30 |
| P/E Ratio | $155.36 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $23.02 | $8.18 |
| 52 Week High | $38.45 | $22.50 |
Technical Indicators
Market Signals| Indicator | WERN | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 54.23 | 43.15 |
| Support Level | $26.64 | $15.22 |
| Resistance Level | $35.46 | $19.98 |
| Average True Range (ATR) | 1.63 | 0.71 |
| MACD | -0.17 | 0.06 |
| Stochastic Oscillator | 73.46 | 36.57 |
Price Performance
Historical ComparisonAbout WERN Werner Enterprises Inc.
Werner Enterprises Inc is a transportation and logistics company. The company has two reportable segments - Truckload Transportation Services and Werner Logistics. It derives majority of its revenue from full-truckload transportation services and geographically from United States.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.